Vitamin D Receptor FokI Gene Polymorphism Predicted Poor Response to Treatment in Chronic HCV Genotype 4

Hany Shehab¹, Dina Sabry¹*, Mai Mukhtar ², Wafaa Elakel¹, Mahasen Mabrouk¹, Amr Zahra³, Gamal Esmat¹, Amany Y El Kazaz^, Amr Zahra³

¹Cairo University, Cairo, Egypt; ²El Talaba hospital, Alexandria, Egypt; ³Fayoum University. Al Fayoum, Egypt; ^Suez Canal University. Ismailia, Egypt.

*Corresponding author: Dina Sabry Abd El Fatah, Professor of Medical Biochemistry and molecular Biology of the Cairo University, Egypt. E-mail:

Published: December 16, 2016.  DOI: 10.21103/Article6(4)_OA3


The aim of this study was to investigate the association between a genetic polymorphism of the vitamin D receptor (VDR) and antiviral responses in Egyptian patients with chronic hepatitis C virus genotype 4 (HCV-4).
Methods: Our study enrolled 100 HCV-4 patients who received pegylated interferon alpha-2a (pegIFNα-2a) and ribavirin for 48 weeks. Patients were divided into 2 groups according to their response to therapy: 50 were responders, and 50 were non-responders. All HCV-4 patients were further subjected to the following laboratory tests: HCV-RNA using quantitative PCR, vitamin D level using ELISA and VDR genotype using PCR-RFLP assays, and abdominal ultrasonography.
Results:  There was a statistically significant difference in the frequency of the VDR polymorphism (FokI rs10735810) between responders (FF: 60%, Ff: 16%, ff: 24%) and non-responders (FF: 10%, Ff: 26%, ff: 64%) (P<0.001). There was a statistically significant association between VDR polymorphism with higher ALT levels (ff: 63.2±30.8, Ff: 48.5±19.5, FF: 54.4±10.8 U/L, p=0.04) and higher alkaline phosphatase levels (ff: 102.6±53.2, Ff: 100.3±66.4, FF: 68.3±29.4 U/L, P=0.007). VDR polymorphism showed no association with baseline vitamin D levels (P=0.21).
 Conclusion: VDR polymorphism plays a role in the treatment response of HCV and the modification of disease progression in Egyptians infected with chronic HCV-4.

HCV genotype 4; response to treatment; vitamin D, FokI polymorphism (rs10735810)
  1. Egyptian Ministry of Health. Annual report: 2007. Available from:
  2.  Kamal SM, Nasser IA. Hepatitis C genotype 4: what we know and what we don’t yet know. Hepatology. 2008; 47:1371–83.
  3.  Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878-87
  4.  Lawitz E, Lalezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis. 2013;13(5):401-8.
  5. Pol S, Ghalib RH, Rustgi VK, Martorell C, Everson GT, Tatum HA, et al. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infect Dis. 2012;12(9):671-7.
  6. Kitson MT, Roberts SK. D-livering the message: the importance of vitamin D status in chronic liver disease J Hepatol. 2012;57(4):897-909
  7. Petta S, Cammà C, Scazzone C, Tripodo C, Di Marco V, Bono A, et al. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology. 2010;51(4):1158–67.
  8. Lange CM, Bojunga J, Ramos-Lopez E, von Wagner M, Hassler A, Vermehren J, et al. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J Hepatol. 2011;54(5):887–93.
  9. Bitetto D, Fattovich G, Fabris C, Ceriani E, Falleti E, Fornasiere E, et al. Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C. Hepatology. 2011;53(4):1118–26.
  10. Kitson MT, Dore GJ, George J, Button P, McCaughan GW, Crawford DH,et al. Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection. J Hepatol. 2013;58(3):467-72.
  11. Abu-Mouch S, Fireman Z, Jarchovsky J, Zeina AR, Assy N. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. World J Gastroenterol. 2011;17(47):5184–90.
  12. Nimer A, Mouch A. Vitamin D improves viral response in hepatitis C genotype 2–3 naïve patients. World J Gastroenterol. 2012;18:800–5.
  13. Zuniga S, Firrincieli D, Housset C, Chignard N. Vitamin D and the vitamin D receptor in liver pathophysiology. Clin Res Hepatol Gastroenterol. 2011; 35(4):295-302.
  14. Mora JR, Iwata M, von Andrian UH. Vitamin effects on the immune system: vitamins A and D take centre stage. Nat Rev Immunol. 2008; 8(9):685-98.
  15. Falleti E, Bitetto D, Fabris C, Cmet S, Fornasiere E, Cussigh A, et al. Association between vitamin D receptor genetic polymorphisms and acute cellular rejection in liver-transplanted patients. Transpl Int.  2012;25(3):314-22
  16. Lange CM, Bibert S, Kutalik Z, Burgisser P, Cerny A, Dufour JF,  et al. A Genetic Validation Study Reveals a Role of Vitamin D Metabolism in the Response to Interferon-Alfa-Based Therapy of Chronic Hepatitis C. PLoS One. 2012;7(7):e40159
  17. García-Martín E, Agúndez JA, Maestro ML, Suárez A, Vidaurreta M, Martínez C, et al. Influence of Vitamin D-Related Gene Polymorphisms (CYP27B and VDR) on the Response to Interferon/Ribavirin Therapy in Chronic Hepatitis C. PLoS One. 2013;8(9):e74764
  18. Fan L, Tu X, Zhu Y, Zhou L, Pfeiffer T, Feltens R, et al. Genetic association of vitamin D receptor polymorphisms with autoimmune hepatitis and primary biliary cirrhosis in the Chinese. J Gastroenterol Hepatol. 2005;20(2):249–55.
  19. Wilkinson RJ, Llewelyn M, Toossi Z, Patel P, Pasvol G, Lalvani A, et al. Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: a case-control study. Lancet. 2000;355(9204):618–21.
  20. Köstner K, Denzer N, Müller CS, Klein R, Tilgen W, Reichrath J. The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. Anticancer Res. 2009;29(9):3511-36.
  21. van Etten E, Mathieu C. Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol. 2005; 97(1-2):93-101.
  22. Adams JS, Liu PT, Chun R, Modlin RL, Hewison M. Vitamin D in defense of the human immune response. Ann N Y Acad Sci. 2007; 1117: 94-105.
  23. Thanapirom K, Suksawatamnuay S, Tangkijvanich P, Treeprasertsuk S, Poovorawan Y, Akkarathamrongsin S, Komolmit P. The Promoter Polymorphism of Cyp27b1 Gene Predicts Poor Response to Interferon-Alfa Based Therapy in Difficult-to-Treat Chronic Hepatitis C Genotype in Asian Population. Gastroenterology. 2013;144(5 Suppl1):S-952
  24. Grammatikos G, Susser S, Schwendy S, et al. Neither vitamin D levels nor genetic polymorphisms within the 25-, and the 1a-vitamin D-hydroxylase are associated with viral clearance following interferon-based therapy in patients with genotype 1 chronic hepatitis C. Hepatology. 2011;54:987A.
  25. Baur K, Mertens JC, Schmitt J, Iwata R, Stieger B, Frei P, et al. The vitamin D receptor gene bAt (CCA) haplotype impairs the response to pegylated-interferon/ribavirin-based therapy in chronic hepatitis C patients. Antivir Ther. 2012;17(3):541-7
  26. Alimirah F, Peng X, Murillo G, Mehta RG. Functional Significance of Vitamin D Receptor FokI Polymorphism in Human Breast Cancer Cells. PLoS One. 2011;6(1):e16024
  27. Liangpunsakul S, Chalasani N. Serum vitamin D concentrations and unexplained elevation in ALT among US adults. Dig Dis Sci. 2011;56(7):2124-9.
  28. Chen HY, Chen WC, Hsu CD, Tsai FJ, Tsai CH. Relation of vitamin D receptor FokI start codon polymorphism to bone mineral density and occurrence of osteoporosis in postmenopausal women in Taiwan. Acta Obstet Gynecol Scand. 2002;81(2):93-8.
  29. Zintzaras E, Rodopoulou P, Koukoulis GN. BsmI, TaqI, ApaI and FokI polymorphisms in the vitamin D receptor (VDR) gene and the risk of osteoporosis: a meta-analysis. Dis Markers. 2006;22(6-8):317-26.
  30. Clark PJ, Thompson AJ, Vock DM, Kratz LE, Tolun AA, Muir AJ, et al. Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner. Hepatology. 2012;56(1):49–56.
  31. Bellecave P, Sarasin-Filipowicz M, Donzé O, Kennel A, Gouttenoire J, Meylan E, et al. Cleavage of mitochondrial antiviral signaling protein in the liver of patients with chronic hepatitis C correlates with a reduced activation of the endogenous interferon system. Hepatology. 2010;51(4):1127–36. 
  32. Vogeser M, Kyriatsoulis A, Huber E, Kobold U. Candidate reference method or the quantification of circulating 25-hyxroxyvitamin D3 by liquid chromatography–tandem mass spectrometry. Clin Chem. 2004;50(8):1415–7.
  33. Uitterlinden AG, Fang Y, Van MeursJB, Pols HA, Van Leeuwen JP. Genetics and biology of vitamin D receptor polymorphisms. Gene. 2004;338(2):143-56.

The fully formatted PDF version is available.
Download Article
Int J Biomed. 2016;6(4):265-270. © 2016 International Medical Research and Development Corporation. All rights reserved.